Sanofi-aventis Strikes Deal to Buy Genzyme

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p89
Trade Publication
The article reports on the agreement reached by Sanofi-Aventis SA and Genzyme Corp. in which French drug maker Sanofi will acquire Genzyme for 20.1 billion U.S. dollars plus additional sum pegged to performance in Paris, France.


Related Articles

  • Sanofi Uses $21.2B Cash, CVR to Win Genzyme.  // Bioworld Week;2/21/2011, Vol. 19 Issue 8, p1 

    The article reports on the acquisition of Genzyme Corp. by French drug maker Sanofi-Aventis SA in a 20.1-billion dollar deal following a nine-month negotiation in the U.S. The takeover was made possible in Sanofi's second attempt after both parties decided to extend negotiations which cover the...

  • The Top 25 U.S. Pharmaceutical Manufacturing Companies.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p93 

    The article reports on the availability of a report entitled "The Top 25 U.S. Pharmaceutical Manufacturing Companies." Among the highlights the report include the nearly 8 billion dollars annual revenue of Gilead Sciences Inc., the acquisition of Genzyme Corp. by Sanofi-Aventis SA and the broad...

  • Sanofi-aventis to buy Ghattem.  // Chain Drug Review;1/4/2010, Vol. 32 Issue 1, p44 

    The article reports on the decision of French drug company Sanofi-Aventis SA to acquire drug developer Chattem Inc. of Chattanooga, Tennessee.

  • Sanofi makes cuts to field force, consolidates functions. Arnold, Matthew // Medical Marketing & Media;Dec2011, Vol. 46 Issue 12, p15 

    The article reports that Sanofi-Aventis SA will carry further reductions to its U.S. sales force and consolidation of several functions following its acquisition of Genzyme Corp.

  • Buyout Value Debate Goes on Despite Campath Data.  // Bioworld Week;10/18/2010, Vol. 18 Issue 42, p5 

    The article reports on the buyout value debate between Cambridge, Massachusetts-based biotech Genzyme Corp. and would acquirer Sanofi-Aventis SA on the 69 U.S. dollar-per-share increase proposal regardless of the data that proved the potential of alemtuzumab to treat multiple sclerosis (MS).

  • Another Genzyme Rejection as Sanofi Bid Turns 'Hostile'.  // Bioworld Week;10/18/2010, Vol. 18 Issue 42, p2 

    The article reports on the disapproval of Genzyme Corp.'s board of the 69 U.S. dollar- to 80 U.S. dollar-per-share offer of Sanofi-Aventis SA in Cambridge, Massachusetts.

  • Sanofi/Genzyme hostile. Ratner, Mark // Nature Biotechnology;Nov2010, Vol. 28 Issue 11, p1142 

    The article discusses the response of Genzyme on the tender offer made by Sanofi-aventis for 69 U.S. dollars per share.

  • sanofi Completes Genzyme Acquisition. Sutton, Stephanie // BioPharm International;May2011, Vol. 24 Issue 5, p12 

    The article reports on the acquisition of Sanofi-Aventis SA on Genzyme Corp. in the U.S. in 2011.

  • Genzyme, Sanofi Discuss Higher Buyout Price: Report.  // MondayMorning;1/10/2011, Vol. 19 Issue 1, p9 

    The article reports that stock prices of drug maker Genzyme Corp. increased by 4% in after-hours trading on January 7, 2011, after the publication of a report which says that French giant Sanofi-Aventis SA has offered a lucrative takeover bid to the company.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics